SA
Log In
GBT
OverviewStreamNotebookIntelChartAnalysts

Analyst Sentiment

Wall St. Consensus
Buy
27 analysts·High coverage
67
Score
18 Buy (67%)9 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1867%
Hold
933%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$36.00
-47.4%
Consensus
$59.00
-13.9%
Bull
$110.00
+60.6%
12-Month Target Range27 analysts
$36.00$59.00$110.00
Current $68.49Consensus
Current Price
$68.49
Above Consensus
$9.49

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

No analyst estimates available

Earnings Surprises

Recent Analyst Actions

Feb 16, 2022Goldman Sachs
Goldman Sachs reiterates Buy Rating on Global Blood Therapeutics (GBT) on Key European Approval
Target:$69.00
+100.3%from $34.44
Feb 8, 2022Jefferies
Jefferies Thinks Global Blood Therapeutics' Stock is Going to Recover
Target:$68.00
+134.2%from $29.04
Jan 7, 2022Wells Fargo
Wells Fargo Thinks Global Blood Therapeutics' Stock is Going to Recover
Target:$70.00
+144.5%from $28.63
Dec 17, 2021Piper Sandler
Piper cautious on Global Blood after 'sobering' Oxbryta comments
Target:$40.00
+30.9%from $30.55
Aug 4, 2021Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Global Blood Therapeutics Shares, Sees 296% Upside For The Stock
Target:$110.00
+241.0%from $32.26
Aug 4, 2021Truist Financial
Global Blood Therapeutics upgraded to Buy from Hold at Truist
Target:$50.00
+55.0%from $32.26
Jun 28, 2021J.P. Morgan
Global Blood Therapeutics downgraded to Neutral from Overweight at JPMorgan
Target:$36.00
+8.5%from $33.19
May 6, 2021Canaccord Genuity
Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug
Target:$40.00
+4.6%from $38.23

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.